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For over a decade there has beenclear evidence for the benefitsof antiplatelet treatment in the
prevention of stroke, myocardial in-
farction and death in patients at high
risk of serious vascular events, includ-
ing people with a history of ischemic
stroke or transient ischemic attack
(TIA), with treatment-related reduc-
tions of about 20%–25% in the relative
risk of serious vascular events.1 Most
of the randomized evidence relates to
ASA, the most widely available and
cheapest of all the antiplatelet drugs.1
Randomized trials comparing the
beneficial effects and hazards of differ-
ent ASA doses have shown that daily
doses of 75–150 mg are as effective as
higher doses and are associated with
fewer adverse effects. Data on ASA
doses under 75 mg/d are still limited.
Direct and indirect comparisons of the
benefits of different doses have not
shown clear differences, but the data
are insufficient to conclude that those
under 75 mg/d are definitely as effec-
tive as dosages of 75 mg/d or more.1
An ASA dose of 75–150 mg/d is there-
fore generally seen as the standard
against which other antiplatelet regi-
mens should be compared.
The past decade has also seen the
emergence of several large trials com-
paring alternative antiplatelet regimens
with ASA. These trials have adopted 2
strategies: comparing another anti-
platelet drug with ASA, or comparing
ASA plus a different antiplatelet drug
with ASA alone. Alternatives to ASA
that have now been directly compared
with ASA for long-term secondary pre-
vention in randomized trials involving
several thousand high-risk patients in-
clude dipyridamole alone or in combi-
nation with ASA, ticlopidine alone,
clopidogrel alone or in combination
with ASA, and triflusal. In this article I
focus on the evidence for use of dipyri-
damole, either alone or in combination
with ASA, as alternatives to ASA alone
for the secondary prevention after an
ischemic stroke or TIA.
Mechanisms of action
ASA exerts its antiplatelet effect by ir-
reversibly inhibiting the enzyme cyclo-
oxygenase. This causes decreased
production of the platelet agonist
thromboxane A2.
Dipyridamole is a pyrimidopyridine
derivative with antiplatelet and vaso-
dilator properties. Its mechanism of ac-
tion on platelets remains a subject of
controversy. Several possible antiplate-
let actions have been observed in vitro,
including inhibition of platelet phos-
phodiesterase, direct stimulation of
prostacyclin release from endothelial
cells and inhibition of adenosine uptake
by platelets. All of these putative mech-
anisms result in an increase in intra-
platelet adenosine 3',5'-cyclic mono-
phosphate (cyclic AMP), which inhibits
the mobilization of free calcium, cen-
tral to platelet activation. Although di-
pyridamole is widely accepted to be an
antiplatelet drug, none of these actions
has been demonstrated in vivo at the
doses of dipyridamole used in clinical
practice.
Dipyridamole is also a vasodilator,
and its coronary dilating effect is the
reason for its use in diagnostic stress
echocardiography and thallium imag-
ing. During rapid intravenous adminis-
tration in these procedures it tends to
cause blood pressure to drop, but in a
randomized comparison of ASA versus
ASA plus 400 mg of dipyridamole
orally (given daily to about 600 patients
with recent cerebral ischemia of arterial
origin, who were followed for an aver-
age of 15 months), the long-term oral
administration of dipyridamole did not
appear to affect blood pressure.2
Evidence from randomized
trials
The most recent systematic review by
the Antithrombotic Trialists’ (ATT) Col-
laboration1 of randomized trials of anti-
platelet treatments for the prevention of
death, myocardial infarction and stroke
in high-risk patients included all data
that were available by September 1997.
Although almost a decade has since
passed and more antiplatelet trials have
emerged, no further randomized trials
have been completed comparing dipyri-
damole (either alone or in combination
with ASA) against ASA alone. The
ATT’s meta-analysis of direct random-
ized comparisons between dipyrida-
mole alone and ASA alone in high-risk
patients found no significant difference
in effect on serious vascular events, in-
cluding stroke, myocardial infarction or
vascular death (odds ratio [OR] 1.02,
95% confidence interval [CI] 0.85–
1.21).1 Since the largest body of evi-
dence for the use of any single anti-
platelet drug is that for ASA, and the
wide confidence interval includes the
possibility that dipyridamole is less ef-
fective than ASA, this implies that dipyr-
idamole alone should not generally be
considered as an alternative to ASA.
Dipyridamole plus ASA was com-
pared with ASA alone in 25 trials in the
ATT overview; overall (Fig. 1), the com-
bination produced a nonsignificant
reduction in serious vascular events (OR
0.94, 95% CI 0.83–1.06). When the sep-
arate components of the composite out-
come were assessed, the combination
appeared to be particularly effective in
reducing nonfatal stroke (OR 0.76,
95% CI 0.62–0.92), but not nonfatal
myocardial infarction (OR 1.13, 95% CI
0.89–1.44) or vascular death (OR 1.03,
95% CI 0.76–1.46; Fig. 1).
The nonfatal stroke result was de-
rived mainly from one large study, the
second European Stroke Prevention
Study (ESPS-2),3 in which about 3000DO
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Analysis
patients with a previous ischemic
stroke or TIA were randomly allocated
to groups given ASA (50 mg) daily 
either with modified-release dipyrida-
mole (400 mg) or alone.3 The other
studies found no difference in nonfatal
stroke outcomes between the com-
bined drugs and ASA alone.1,3 The
favourable results for stroke from the
ESPS-2 trial could be explained by
chance (since the number of patients
and relevant outcome events was rela-
tively small), the dose of ASA used
(since 50 mg might be less effective
than 75 mg or more daily) or the partic-
ular dose and preparation of dipyrida-
mole used. Analyses that included only
trials with ischemic stroke and TIA pa-
tients, or that considered only the
ESPS-2 trial (the only study to use the
modified-release preparation of dipyri-
damole), suggest that the combination
reduces vascular events compared with
ASA alone,3,4 but since these results are
also dominated by the stroke outcomes
in the ESPS-2 study, they are also sub-
ject to the possible effects of chance
and the very low dose of ASA. So, al-
though the addition of modified-
release dipyridamole to ASA may re-
duce the risk of recurrent stroke and
vascular events in patients with a prior
ischemic stroke or TIA, in my view this
remains uncertain.
The nonsignificant trend toward an
increased risk of nonfatal myocardial
infarction with the combination of di-
pyridamole and ASA (compared with
ASA alone; see Fig. 1) has made some
clinicians anxious about using the drug
combination in patients with ischemic
stroke and TIA who also have a history
of ischemic heart disease and may be at
high risk of subsequent infarction.
Some reassurance is available from an-
alyses restricted to trials among pa-
tients with ischemic stroke or TIA, and
from a post hoc subgroup analysis of
patients with prior ischemic heart dis-
ease in the ESPS-2 trial: in neither case
did the combination increase the risk
of myocardial infarction over that of
ASA alone.4,5
Adverse effects
The ATT overview found no evidence
that the combination of ASA and dipyr-
idamole caused major hemorrhage any
more than did ASA alone.1 Dipyrida-
mole is, however, associated with other
adverse effects, diarrhea and headache
in particular. In the largest randomized
trial assessing the combination of
dipyridamole plus ASA versus ASA
alone,3 more premature cessations of
study treatment occurred owing to ad-
verse effects with the combination
(262/1650 = 15.9%) than with ASA
alone (141/1649 = 8.6%).
What should clinicians do?
Additional evidence on the effectiveness
of the combination of dipyridamole and
ASA will be available in a few years,
from the ongoing European–Australian
Stroke Prevention in Reversible Ischae-
mia Trial (ESPRIT), in which some
3000 patients with a prior ischemic
stroke or TIA are being randomly as-
signed to receive ASA alone or in com-
bination with dipyridamole (400 mg)
daily (see www.strokecenter.org/trials
/TrialDetail.aspx?tid=16). Until then,
recommendations for the routine use,
after an ischemic stroke or TIA, of mod-
ified-release dipyridamole plus ASA
rather than ASA alone (75–150 mg/d)
(e.g., as per the guidelines at www.nice
.org.uk/pdf/TA090guidance.pdf from
the United Kingdom’s National Insti-
tute for Health and Clinical Excellence)
seem to me to go beyond what is justi-
fied by the current evidence.
Some stroke physicians may favour
adding modified-release dipyridamole
to ASA if the patient experiences an is-
chemic cerebrovascular event while al-
ready taking ASA, on the basis that
these patients are likely to be at particu-
larly high risk and it seems more rea-
sonable to do something than nothing.
In my view, this reaction is rarely justi-
fied. No randomized trial addressing
this specific issue has been completed,
and the effect of adding another med-
ication of uncertain additional benefit
may simply be to reduce compliance
with those already prescribed.
It is far more important to ensure
that the diagnosis is really correct and,
if so, that such patients really are taking
daily ASA (or an oral anticoagulant, if
atrial fibrillation is present and there
are no contraindications), along with
an appropriate dose of a statin and ade-
quate blood-pressure–lowering treat-
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Vascular
events 25 10 404 11.8 12.5 0.94 (0.83–1.06) 
Nonfatal
myocardial
infarction 21  9 353 3.2 2.9 1.13 (0.89–1.44)
Nonfatal 
stroke 20  8 851 4.1 5.4 0.76 (0.62–0.92) 
Vascular 
death 25 10 404 5.5 5.4 1.03 (0.87–1.22)
0 0.5 1 1.5 2
ASA + dipyridamole better                        ASA better
Outcome
No. of
trials
No. of
patients
ASA + 
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% 
ASA,
% Odds ratio (95% CI) 
Fig. 1: Meta-analysis of randomized trials of dipyridamole in combination with ASA versus
ASA alone in high-risk patients, using data from the Antithrombotic Trialists’ Collaboration1
for the effects on vascular events, combined and separately. Odds ratios are shown as
squares of a size proportional to the inverse variance of the odds ratio for that outcome; the
95% confidence interval (CI) for each vascular outcome is indicated by a horizontal bar.
ment; that they have made appropriate
modifications to their lifestyle (espe-
cially cessation of smoking); and, if ap-
propriate, that they undergo an ade-
quate and timely assessment of their
suitability for carotid endarterectomy.
Cathie Sudlow
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